norethindrone has been researched along with Cardiovascular Diseases in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (20.75) | 18.7374 |
| 1990's | 9 (16.98) | 18.2507 |
| 2000's | 28 (52.83) | 29.6817 |
| 2010's | 5 (9.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baracat, EC; Fernandes, CE; Lakryc, EM; Machado, RB; Soares, JM | 1 |
| Johansen, OE; Qvigstad, E | 1 |
| Bruce, D; Frick, A; Robinson, J; Rymer, J; Ylikorkala, O | 1 |
| Angelova, M; Monastirska, M; Tsvetkov, K | 1 |
| Bingol, B; Biri, A; Gunenc, Z; Güner, H; Tiras, B; Yilmaz, M | 1 |
| Weisberg, E | 1 |
| de Melo, NR | 1 |
| Borowiecka, M; Nowak, P; Połać, I; Wilamowska, A | 1 |
| Graff-Iversen, S; Tonstad, S | 1 |
| Jamin, C; Madelenat, P; Poncelet, C | 1 |
| Strandberg, TE; Tikkanen, MJ; Ylikorkala, O | 1 |
| Dhindsa, P; Forsyth, J; Mansell, P; Scott, AR | 1 |
| Crawford, L; Gallacher, S; Greer, IA; Jaap, AJ; Kelly, A; Lowe, GD; McKenzie, J; Paterson, K; Petrie, JR; Rumley, A; Sattar, N | 1 |
| Guilford, S; Manassiev, N; Oladipo, A; Proudler, AJ; Stevenson, JC; Whitehead, MI | 1 |
| Graff-Iversen, S; Hammar, N; Thelle, DS; Tonstad, S | 1 |
| Durrington, PN; Kwok, S; Laing, I; Mackness, B; Mackness, MI; McElduff, P; Morgan, J; Prais, H; Sci, FM; Selby, PL; Yates, AP | 1 |
| Baviera, G; Cancellieri, F; Corrado, F; Crisafulli, A; D'Anna, R; Squadrito, F | 1 |
| Anderson, S; Durrington, PN; Gibson, MJ; Heald, A; Kaushal, K; Redpath, M; Selby, PL | 1 |
| Cleland, SJ; Hillier, C; Kernohan, AF; Lumsden, MA; McConnell, J; Petrie, JR; Sattar, N; Small, M; Spiers, A | 1 |
| Bergstrøm, H; Tonstad, S | 1 |
| Cleland, SJ; Connell, JM; Hilditch, T; Kernohan, AF; Lumsden, MA; Petrie, JR; Sattar, N; Small, M | 1 |
| Brosnan, JF; Norris, LA; Sheppard, BL | 1 |
| Demircan, S; Kizilkaya, K; Köseoğlu, K; Odabasi, AR; Onur, E; Yüksel, H | 1 |
| Karul, A; Kozaci, D; Odabasi, AR; Onur, E; Sezer, SD; Yuksel, H | 1 |
| Kuhl, H; Wiegratz, I | 1 |
| Brook, RD; Duvernoy, CS; Kehrer, C; Kim, HM; Rose, PA | 1 |
| Kay, CR | 1 |
| Niththyananthan, R; Wynn, V | 1 |
| Meade, TW | 1 |
| Roberts, JM | 1 |
| Greenberg, G; Meade, TW; Thompson, SG | 1 |
| Mück, AO; Rabe, T; Runnebaum, B; Salbach, B; von Holst, T | 1 |
| Crook, D; Devenport, M; Godsland, IF; Wynn, V | 1 |
| Taskinen, MR | 1 |
| Crook, D; Godsland, IF; Lees, B; Stevenson, JC; Whitehead, MI | 1 |
| Graff-Iversen, S; Stensvold, I; Tverdal, A | 1 |
| Bjäörn, M; Ehnholm, C; Kääriänen, J; Lahdenperä, S; Luotola, H; Puolakka, J; Pyörälä, T; Taskinen, MR | 1 |
| Berg, G; Brenner, H; Kohlmeier, L | 1 |
| Belch, JJ; Kennedy, G; McLaren, M; Seed, M | 1 |
| Arce, JC; Cyrowski, MS; Davidson, MH; Maki, AC; Maki, KC; Marx, P; Nanavati, N | 1 |
| Fritz-Hansen, T; Højgaard, L; Jensen, HH; Ottesen, B; Pedersen, AT; Sørensen, MB | 1 |
| Bilgin, O; Karadadaş, N; Sendağ, F; Terek, MC | 1 |
| Chondros, C; Christodoulakos, G; Creatsas, G; Dendrinos, S; Kouskouni, E; Panoulis, C | 1 |
| Bilgin, O; Karadadas, N; Ozsener, S; Sendag, F | 1 |
| Nerbrand, C; Nordström, L; Nyberg, P; Samsioe, G | 1 |
| Jensen, GF; McNair, P; Myrup, B | 1 |
| Dubnitskaia, LV; Korsakov, SG; Manuilova, IA | 1 |
| Keller, PJ | 1 |
| Hoppe, G | 1 |
| Policar, M | 1 |
| Oakley, C; Somerville, J | 1 |
6 review(s) available for norethindrone and Cardiovascular Diseases
| Article | Year |
|---|---|
Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg.
Topics: Antidepressive Agents; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Diet; Dose-Response Relationship, Drug; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Humans; Menopause; Norethindrone; Norethindrone Acetate | 2008 |
Estrogen-free oral hormonal contraception: benefits of the progestin-only pill.
Topics: Cardiovascular Diseases; Contraceptives, Oral, Combined; Contraceptives, Oral, Synthetic; Dysmenorrhea; Female; Humans; Medication Adherence; Menstruation; Norethindrone; Progestins | 2010 |
[Tibolone].
Topics: Adult; Aged; Animals; Blood Coagulation; Breast; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Double-Blind Method; Endometrium; Estradiol; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Humans; Hysterectomy; Lipid Metabolism; Lipids; Medrogestone; Menopause; Middle Aged; Norethindrone; Norethindrone Acetate; Norpregnenes; Osteoporosis, Postmenopausal; Ovariectomy; Placebos; Postmenopause; Progesterone Congeners; Prospective Studies; Rabbits; Rats; Risk Factors; Surveys and Questionnaires; Time Factors | 2002 |
Can 19-nortestosterone derivatives be aromatized in the liver of adult humans? Are there clinical implications?
Topics: Androgens; Aromatase; Breast Diseases; Cardiovascular Diseases; Ethinyl Estradiol; Female; Humans; Hyperlipoproteinemias; Liver; Nandrolone; Norethindrone; Norethynodrel; Norpregnenes; Uterine Diseases | 2007 |
Oestrogens and hypertension.
Topics: Adolescent; Adult; Age Factors; Angiotensin II; Cardiac Output; Cardiovascular Diseases; Contraceptives, Oral; Estrogens; Female; Humans; Hypertension; Menopause; Middle Aged; Norethindrone; Norethindrone Acetate; Pituitary-Adrenal System; Progestins; Prospective Studies; Prostaglandins; Renin; Renin-Angiotensin System; Sympathetic Nervous System | 1981 |
[Hormonal contraception using depot preparations].
Topics: Abnormalities, Drug-Induced; Blood Coagulation; Carbohydrate Metabolism; Cardiovascular Diseases; Contraceptive Agents, Female; Delayed-Action Preparations; Female; Humans; Infant, Newborn; Levonorgestrel; Liver; Medroxyprogesterone; Medroxyprogesterone Acetate; Neoplasms; Norethindrone; Norgestrel; Pregnancy; Risk | 1986 |
30 trial(s) available for norethindrone and Cardiovascular Diseases
| Article | Year |
|---|---|
What is the influence of hormone therapy on homocysteine and crp levels in postmenopausal women?
Topics: Age Factors; Brazil; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Follow-Up Studies; Homocysteine; Humans; Longitudinal Studies; Middle Aged; Norethindrone; Norethindrone Acetate; Patient Dropouts; Postmenopause; Progestins; Prospective Studies | 2015 |
A comparison of hormone therapies on the urinary excretion of prostacyclin and thromboxane A2.
Topics: Cardiovascular Diseases; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Epoprostenol; Estradiol; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Norethindrone; Norethindrone Acetate; Norpregnenes; Raloxifene Hydrochloride; Thromboxane A2 | 2008 |
[Using pausogest for hormone replacement therapy--effect on plasma lipoproteins in menopause women].
Topics: Cardiovascular Diseases; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Female; Humans; Lipoproteins; Menopause; Middle Aged; Norethindrone; Norethindrone Acetate; Prospective Studies; Treatment Outcome | 2008 |
Effects of hormone replacement therapy on glucose and lipid profiles and on cardiovascular risk parameters in postmenopausal women.
Topics: Biomarkers; Blood Glucose; C-Reactive Protein; Carbohydrate Metabolism; Cardiovascular Diseases; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Fibrinogen; Homocysteine; Humans; Inflammation; Lipid Metabolism; Lipoproteins; Middle Aged; Norethindrone; Norethindrone Acetate; Postmenopause; Risk Factors | 2010 |
Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
Topics: Administration, Oral; Blood Coagulation; Cardiovascular Diseases; Drug Combinations; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Fibrinolysis; Humans; Menopause; Middle Aged; Norethindrone; Poland; Postmenopause; Progestins; Risk Factors; Transdermal Patch; Venous Thrombosis | 2013 |
Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women.
Topics: Administration, Cutaneous; Administration, Oral; Age Factors; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Contraceptives, Oral, Combined; Drug Combinations; Estradiol; Estriol; Estrogen Replacement Therapy; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Middle Aged; Norethindrone; Reference Values; Risk Factors | 2003 |
Comparative study of the effects of two once-a-month injectable contraceptives (Cyclofem and Mesigyna) and one oral contraceptive (Ortho-Novum 1/35) on coagulation and fibrinolysis.
Topics: Adolescent; Adult; Antithrombins; Blood Coagulation; Cardiovascular Diseases; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Drug Combinations; Estradiol; Factor VII; Factor X; Female; Fibrinogen; Fibrinolysis; Hemoglobins; Humans; Injections; Medroxyprogesterone Acetate; Mestranol; Norethindrone; Partial Thromboplastin Time; Plasminogen; Plasminogen Inactivators; Platelet Count; Protein C; Prothrombin | 2003 |
Effect of hormone replacement therapy on cardiovascular risk factors in postmenopausal women with diabetes.
Topics: Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Female; Humans; Lipids; Middle Aged; Norethindrone; Norethindrone Acetate; Postmenopause; Risk Factors | 2004 |
Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?
Topics: Autoantigens; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Estradiol; Estrogen Replacement Therapy; Factor VII; Female; Humans; Interleukin-6; Linear Models; Menopause; Middle Aged; Norethindrone; Risk Factors; Tissue Plasminogen Activator; Triglycerides | 2003 |
Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers.
Topics: Administration, Cutaneous; Adult; Anthropometry; Biomarkers; Blood Glucose; Cardiovascular Diseases; Delayed-Action Preparations; Drug Combinations; Epidemiologic Methods; Estradiol; Estrogen Replacement Therapy; Female; Hemostasis; Humans; Insulin; Lipids; Lipoproteins; Middle Aged; Norethindrone; Norethindrone Acetate; Postmenopause | 2004 |
Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy.
Topics: Aryldialkylphosphatase; Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Desogestrel; Drug Administration Schedule; Estrogen Replacement Therapy; Female; Fibrinogen; Humans; Insulin; Lipoproteins; Medroxyprogesterone; Middle Aged; Norethindrone; Postmenopause; Progestins; Risk Factors; Statistics, Nonparametric; Triglycerides | 2004 |
The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women.
Topics: C-Reactive Protein; Cardiovascular Diseases; Estradiol; Estrogen Replacement Therapy; Female; Genistein; Homocysteine; Humans; Middle Aged; Norethindrone; Norethindrone Acetate; Phytoestrogens; Postmenopause; Treatment Outcome | 2005 |
Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
Topics: Blood Glucose; Cardiovascular Diseases; Desogestrel; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Insulin; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Postmenopause; Progestins; Risk Factors | 2005 |
Effects of low-dose continuous combined HRT on vascular function in women with type 2 diabetes.
Topics: Arteries; Biopsy; Blood Flow Velocity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Endothelium, Vascular; Estradiol; Estrogen Replacement Therapy; Female; Humans; Intercellular Adhesion Molecule-1; Middle Aged; Norethindrone; Vascular Cell Adhesion Molecule-1; Vascular Resistance; Vasoconstriction; Vasodilation | 2004 |
Combined hormone replacement therapy improves lipids but may increase leucocytes.
Topics: Administration, Oral; Adult; Aged; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Cholinergic Antagonists; Double-Blind Method; Estradiol; Estrogen Replacement Therapy; Female; Humans; Leukocytes; Middle Aged; Norethindrone; Norethindrone Acetate; Postmenopause | 2006 |
Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes.
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Estradiol; Estrogen Replacement Therapy; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Norethindrone; Postmenopause; Risk Factors; Statistics, Nonparametric; Triglycerides | 2007 |
Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?
Topics: Administration, Cutaneous; Administration, Oral; Aged; alpha-2-Antiplasmin; Antigens; Antithrombins; Blood Coagulation; Cardiovascular Diseases; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Factor VII; Female; Fibrinogen; Fibrinolysin; Fibrinolysis; Humans; Ireland; Middle Aged; Norethindrone; Norethindrone Acetate; Peptide Fragments; Postmenopause; Prothrombin; Risk Factors; Time Factors; Tissue Plasminogen Activator; Treatment Outcome | 2007 |
Effects of postmenopausal hormone replacement therapy on body fat composition.
Topics: Abdominal Fat; Administration, Cutaneous; Administration, Oral; Adult; Body Fat Distribution; Body Weight; Cardiovascular Diseases; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Risk Factors; Waist-Hip Ratio | 2007 |
Effects of standard and low dose 17beta-estradiol plus norethisterone acetate on body composition and leptin in postmenopausal women at risk of body mass index and waist girth related cardiovascular and metabolic disease.
Topics: Body Composition; Body Mass Index; Cardiovascular Diseases; Estradiol; Female; Hormone Replacement Therapy; Humans; Leptin; Metabolic Diseases; Middle Aged; Norethindrone; Norethindrone Acetate; Postmenopause; Prospective Studies; Single-Blind Method; Waist-Hip Ratio | 2007 |
Combined continuous ethinyl estradiol/norethindrone acetate does not improve forearm blood flow in postmenopausal women at risk for cardiovascular events: a pilot study.
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Endothelin-1; Estrogen Replacement Therapy; Ethinyl Estradiol; Female; Forearm; Humans; Middle Aged; Norethindrone; Pilot Projects; Plasminogen Activator Inhibitor 1; Postmenopause; Regional Blood Flow; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Women's Health | 2007 |
Oral versus transdermal hormone replacement therapy.
Topics: Administration, Cutaneous; Administration, Oral; Blood Glucose; Bone Density; Cardiovascular Diseases; Cholesterol; Estradiol; Estrogen Replacement Therapy; Female; Humans; Insulin; Lipoproteins; Longitudinal Studies; Menopause; Norethindrone; Norethindrone Acetate; Norgestrel; Progesterone Congeners; Triglycerides; White People | 1993 |
Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens.
Topics: Administration, Cutaneous; Administration, Oral; Cardiovascular Diseases; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Female; Humans; Lipoprotein(a); Lipoproteins, HDL; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Norethindrone Acetate; Postmenopause; Progesterone Congeners; Risk Factors | 1996 |
Elevated levels of sE-selectin in post-menopausal females are decreased by hormone replacement therapy to levels observed in pre-menopausal females.
Topics: Adult; Aged; Cardiovascular Diseases; Drug Synergism; E-Selectin; Endothelium, Vascular; Estradiol; Estrogen Replacement Therapy; Female; Humans; Lipids; Male; Middle Aged; Norethindrone; Norethindrone Acetate; Postmenopause; Premenopause; Risk Factors; Sex Characteristics; Solubility; von Willebrand Factor | 1999 |
Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.
Topics: Aged; Apolipoprotein A-I; Blood Coagulation Factors; Blood Glucose; C-Peptide; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Estradiol; Estrogen Replacement Therapy; Female; Glycated Hemoglobin; Humans; Insulin; Lipids; Lipoprotein(a); Middle Aged; Norethindrone; Norethindrone Acetate; Postmenopause; Risk Factors; Treatment Outcome; Triglycerides | 2000 |
Temporal changes in cardiac function and cerebral blood flow during sequential postmenopausal hormone replacement.
Topics: Blood Pressure; Cardiovascular Diseases; Cerebrovascular Circulation; Cross-Over Studies; Double-Blind Method; Estradiol; Estrogen Replacement Therapy; Female; Heart; Humans; Magnetic Resonance Angiography; Middle Aged; Norethindrone; Norethindrone Acetate; Placebos; Postmenopause; Stroke Volume; Vascular Resistance | 2001 |
Effects of oral and transdermal hormone replacement therapy on internal carotid artery pulsatility indices in postmenopausal women. A prospective, randomized, comparative study.
Topics: Administration, Cutaneous; Administration, Oral; Cardiovascular Diseases; Carotid Artery, Internal; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Norethindrone Acetate; Progesterone Congeners; Prospective Studies; Pulsatile Flow | 2001 |
Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis.
Topics: Cardiovascular Diseases; Double-Blind Method; Endothelin-1; Epoprostenol; Estradiol; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Nitric Oxide; Norethindrone; Norethindrone Acetate; Placebos; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2002 |
Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women.
Topics: Administration, Cutaneous; Administration, Oral; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follicle Stimulating Hormone; Humans; Lipids; Lipoproteins; Luteinizing Hormone; Middle Aged; Norethindrone; Norethindrone Acetate; Postmenopause; Prospective Studies; Triglycerides | 2002 |
Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides.
Topics: Administration, Oral; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Estrogen Replacement Therapy; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Middle Aged; Norethindrone; Obesity; Postmenopause; Treatment Outcome; Triglycerides | 2002 |
Cardiovascular risk factors during estrogen-norethindrone and cholecalciferol treatment.
Topics: Aged; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cholecalciferol; Cholesterol; Cholesterol, HDL; Denmark; Double-Blind Method; Drug Combinations; Estradiol; Estriol; Estrogen Replacement Therapy; Female; Humans; Norethindrone; Risk Factors; Time Factors | 1992 |
17 other study(ies) available for norethindrone and Cardiovascular Diseases
| Article | Year |
|---|---|
Contraceptive options for women in selected circumstances.
Topics: Adolescent; Adult; Anemia; Breast Diseases; Cardiovascular Diseases; Condoms; Contraception; Contraceptive Agents, Female; Contraindications; Desogestrel; Diabetes Mellitus; Drug Combinations; Drug Implants; Epilepsy; Ethinyl Estradiol; Female; Heart Valve Diseases; Humans; Hypertension; Inflammatory Bowel Diseases; Injections; Intrauterine Devices; Levonorgestrel; Liver Diseases; Lupus Erythematosus, Systemic; Medroxyprogesterone Acetate; Migraine Disorders; Norethindrone; Norgestrel; Obesity; Patient Preference; Pregnancy; Progestins; Stroke; Young Adult | 2010 |
Use of progestogen-only contraceptives/medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian Survey.
Topics: Administration, Oral; Adult; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Cholesterol, HDL; Cross-Sectional Studies; Delayed-Action Preparations; Female; Health Surveys; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Lipoproteins; Lynestrenol; Medroxyprogesterone Acetate; Norethindrone; Norway; Progestins; Risk Factors; Triglycerides | 2002 |
Hormone therapy and mortality during a 14-year follow-up of 14 324 Norwegian women.
Topics: Adult; Cardiovascular Diseases; Cause of Death; Coronary Disease; Estradiol; Female; Follow-Up Studies; Hormone Replacement Therapy; Humans; Levonorgestrel; Middle Aged; Norethindrone; Norway; Regression Analysis | 2004 |
Progestogens and arterial disease--evidence from the Royal College of General Practitioners' study.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Contraceptives, Oral; Contraceptives, Oral, Synthetic; England; Ethinyl Estradiol; Female; Humans; Levonorgestrel; Lipoproteins, HDL; Norethindrone; Norethindrone Acetate; Norgestrel; Progesterone Congeners; Prospective Studies | 1982 |
The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Contraceptives, Oral; Contraceptives, Oral, Hormonal; Female; Humans; Levonorgestrel; Lipids; Lipoproteins, HDL; Norethindrone; Norethindrone Acetate; Norgestrel; Progesterone Congeners; Triglycerides | 1982 |
Effects of progestogens on the cardiovascular system.
Topics: Adult; Cardiovascular Diseases; Cerebrovascular Disorders; Contraceptives, Oral; Contraceptives, Oral, Hormonal; Coronary Disease; Estrogens; Female; Humans; Hypertension; Levonorgestrel; Norethindrone; Norethindrone Acetate; Norgestrel; Progestins | 1982 |
Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations.
Topics: Cardiovascular Diseases; Contraceptives, Oral; Dose-Response Relationship, Drug; Drug Combinations; Ethinyl Estradiol; Female; Humans; Norethindrone; Norgestrel; Thrombophlebitis | 1980 |
[Serum lipids in treatment with transdermal estradiol and oral norethisterone acetate].
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Climacteric; Dose-Response Relationship, Drug; Estradiol; Estrogen Replacement Therapy; Female; Humans; Lipids; Middle Aged; Norethindrone; Norethindrone Acetate; Triglycerides | 1995 |
Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Blood Pressure; C-Peptide; Cardiovascular Diseases; Cholesterol, HDL; Contraceptives, Oral, Combined; Contraceptives, Oral, Synthetic; Desogestrel; Ethinyl Estradiol; Female; Glucose Tolerance Test; Humans; Hypertension; Insulin; Levonorgestrel; Middle Aged; Norethindrone; Risk Factors | 1995 |
Postmenopausal hormone replacement therapy and plasma lipoproteins.
Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Double-Blind Method; Drug Combinations; Estrogen Replacement Therapy; Estrogens; Female; Humans; Lipoproteins; Medroxyprogesterone Acetate; Middle Aged; Multicenter Studies as Topic; Norethindrone; Norethindrone Acetate; Norgestrel; Postmenopause; Progesterone Congeners; Progestins; Randomized Controlled Trials as Topic; Risk Factors | 1995 |
Cardiovascular risk factors in Norwegian women using oral contraceptives: results from a cardiovascular health screening 1985-88.
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Contraceptive Agents, Female; Contraceptives, Oral, Synthetic; Coronary Disease; Desogestrel; Estradiol; Female; Health Surveys; Humans; Levonorgestrel; Lipids; Lynestrenol; Middle Aged; Norethindrone; Norway; Progesterone Congeners; Prospective Studies; Risk Factors; Smoking; Surveys and Questionnaires | 1996 |
Effect of oral contraceptive progestins on serum copper concentration.
Topics: Adolescent; Adult; Androgen Antagonists; Cardiovascular Diseases; Contraceptives, Oral; Copper; Cross-Sectional Studies; Desogestrel; Female; Humans; Levonorgestrel; Norethindrone; Progesterone Congeners; Progestins; Surveys and Questionnaires | 1998 |
[Changes in arterial blood pressure of women using hormonal contraceptives in relation to their cardiovascular history].
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Chlormadinone Acetate; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Disease Susceptibility; Drug Combinations; Ethinyl Estradiol; Ethinyl Estradiol-Norgestrel Combination; Female; Humans; Hypertension; Middle Aged; Norethindrone; Norgestrel; Risk Factors | 1989 |
Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Contraceptives, Oral, Synthetic; Desogestrel; Female; Humans; Levonorgestrel; Lipoproteins; Norethindrone; Norgestrel; Norpregnenes; Population Surveillance; Progesterone Congeners; Prospective Studies; Risk | 1987 |
Oral contraception, 1986. Endocrinology and pharmacology. A panel discussion.
Topics: Adult; Animals; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Contraceptives, Oral, Synthetic; Drug Administration Schedule; Ethinyl Estradiol; Female; Genital Neoplasms, Female; Humans; Mestranol; Middle Aged; Norethindrone; Norgestrel; Rats; Risk | 1986 |
Clinical experience with multiphasic oral contraceptives.
Topics: Adult; Carbohydrate Metabolism; Cardiovascular Diseases; Contraceptives, Oral, Combined; Ethinyl Estradiol; Female; Humans; Lipid Metabolism; Middle Aged; Norethindrone; Progesterone Congeners; Substance Withdrawal Syndrome; Uterine Hemorrhage; Virilism | 1986 |
Oral contraceptives and progressive pulmonary vascular disease.
Topics: Adult; Cardiovascular Diseases; Contraceptives, Oral; Ethinyl Estradiol; Female; Heart Defects, Congenital; Humans; Lynestrenol; Mestranol; Norethindrone; Norethynodrel; Pregnancy; Pulmonary Circulation | 1968 |